Literature DB >> 16200142

Diagnostic molecular pathology, part 2: proteomics and clinical applications of molecular diagnostics in hematopathology.

Georges J Netto1, Rana Saad.   

Abstract

Year:  2005        PMID： 16200142      PMCID： PMC1200694          DOI： 10.1080/08998280.2005.11928025

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


× No keyword cloud information.
  29 in total

1.  The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification.

Authors:  Haleem J Issaq; Timothy D Veenstra; Thomas P Conrads; Donna Felschow
Journal:  Biochem Biophys Res Commun       Date:  2002-04-05       Impact factor: 3.575

Review 2.  Proteomic applications for the early detection of cancer.

Authors:  Julia D Wulfkuhle; Lance A Liotta; Emanuel F Petricoin
Journal:  Nat Rev Cancer       Date:  2003-04       Impact factor: 60.716

3.  Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis.

Authors:  N Cohen; G Rozenfeld-Granot; I Hardan; F Brok-Simoni; N Amariglio; G Rechavi; L Trakhtenbrot
Journal:  Cancer Genet Cytogenet       Date:  2001-07-15

4.  Immunoglobulin heavy chain gene analysis in lymphomas: a multi-center study demonstrating the heterogeneity of performance of polymerase chain reaction assays.

Authors:  Adam Bagg; Rita M Braziel; Daniel A Arber; Karen E Bijwaard; Albert Y Chu
Journal:  J Mol Diagn       Date:  2002-05       Impact factor: 5.568

5.  Use of proteomic patterns in serum to identify ovarian cancer.

Authors:  Emanuel F Petricoin; Ali M Ardekani; Ben A Hitt; Peter J Levine; Vincent A Fusaro; Seth M Steinberg; Gordon B Mills; Charles Simone; David A Fishman; Elise C Kohn; Lance A Liotta
Journal:  Lancet       Date:  2002-02-16       Impact factor: 79.321

6.  Chronic myelogenous leukemia in blast crisis: retrospective analysis of prognostic factors in 90 patients.

Authors:  M Griesshammer; B Heinze; A Hellmann; C Popp; B Anger; G Heil; M Bangerter; H Heimpel
Journal:  Ann Hematol       Date:  1996-11       Impact factor: 3.673

Review 7.  Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia.

Authors:  Brian J P Huntly; Anthony Bench; Anthony R Green
Journal:  Blood       Date:  2003-05-01       Impact factor: 22.113

8.  Fluorescence in situ hybridization identifies cryptic t(16;16)(p13;q22) masked by del(16)(q22) in a case of AML-M4 Eo.

Authors:  Shakil H Merchant; Skip Haines; Bryan Hall; John Hozier; David S Viswanatha
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

Review 9.  Tyrosine kinase inhibitors in cancer therapy.

Authors:  Srinivasan Madhusudan; Trivadi S Ganesan
Journal:  Clin Biochem       Date:  2004-07       Impact factor: 3.281

10.  The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate.

Authors:  Eric Feldman; Vesna Najfeld; Michael Schuster; Gail Roboz; Amy Chadburn; Richard T Silver
Journal:  Exp Hematol       Date:  2003-08       Impact factor: 3.084
View more
  2 in total

Review 1.  Cell-blocks and other ancillary studies (including molecular genetic tests and proteomics).

Authors:  Vinod B Shidham
Journal:  Cytojournal       Date:  2021-02-22       Impact factor: 2.091

2.  Pseudo-HE images derived from CARS/TPEF/SHG multimodal imaging in combination with Raman-spectroscopy as a pathological screening tool.

Authors:  Thomas W Bocklitz; Firas Subhi Salah; Nadine Vogler; Sandro Heuke; Olga Chernavskaia; Carsten Schmidt; Maximilian J Waldner; Florian R Greten; Rolf Bräuer; Michael Schmitt; Andreas Stallmach; Iver Petersen; Jürgen Popp
Journal:  BMC Cancer       Date:  2016-07-26       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.